CD38 and Miyoshi myopathy: The recent advent of chimeric antigen receptor (CAR) T-cell therapy [24] and bispecific T-cell engager (BiTE) therapy [25] has led to promising outcomes in patients with anti-CD38 mAb-refractory MM.